Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Konstantinos Xynos sold 16,198 shares of the firm's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $21.60, for a total transaction of $349,876.80. Following the completion of the transaction, the insider owned 208,017 shares of the company's stock, valued at approximately $4,493,167.20. The trade was a 7.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Trading Up 0.6%
Shares of Replimune Group stock traded up $0.12 during trading on Wednesday, hitting $19.81. The stock had a trading volume of 2,130,078 shares, compared to its average volume of 3,489,130. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $23.54. The stock has a 50 day simple moving average of $15.10 and a 200 day simple moving average of $10.23. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $1.88 billion, a PE ratio of -7.10 and a beta of 0.93.
Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. On average, research analysts expect that Replimune Group, Inc. will post -2.38 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter valued at $99,171,000. Marshall Wace LLP acquired a new stake in Replimune Group during the third quarter valued at $50,516,000. Opaleye Management Inc. acquired a new stake in Replimune Group during the second quarter valued at $15,332,000. EcoR1 Capital LLC acquired a new stake in Replimune Group during the first quarter valued at $7,650,000. Finally, ADAR1 Capital Management LLC purchased a new position in Replimune Group in the second quarter valued at about $7,260,000. Institutional investors and hedge funds own 92.53% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. Wall Street Zen upgraded Replimune Group from a "sell" rating to a "hold" rating in a report on Saturday, October 31st. Cantor Fitzgerald reissued an "overweight" rating on shares of Replimune Group in a research report on Monday, October 5th. Wolfe Research raised Replimune Group to an "outperform" rating in a research note on Tuesday, August 4th. Weiss Ratings reissued a "sell (e+)" rating on shares of Replimune Group in a research note on Wednesday, November 4th. Finally, Piper Sandler raised their price objective on Replimune Group from $14.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Replimune Group has an average rating of "Moderate Buy" and a consensus price target of $18.17.
Get Our Latest Report on Replimune Group
Replimune Group Company Profile
(
Get Free Report)
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company's investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.